Ixekizumab‐induced urticarial drug eruption
Abstract Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL‐17A, which exhibited high...
Saved in:
Main Authors: | Ayaka Kaneoka (Author), Natsuko Saito‐Sasaki (Author), Etsuko Okada (Author), Yu Sawada (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fixed Drug Eruption due to Dupilumab
by: Ayaka Kaneoka, et al.
Published: (2024) -
Urticarial drug eruption following tocilizumab administration
by: Hikaru Nanamori, et al.
Published: (2022) -
A Case of Ixekizumab-induced Psoriasiform Eruption
by: Tomohiro Oiwa, et al.
Published: (2019) -
Urticarial eruption in COVID-19-positive children: A report of two cases
by: Shikhar Ganjoo, et al.
Published: (2022) -
Tranexamic acid-induced fixed drug eruption
by: Natsuko Matsumura, et al.
Published: (2015)